[HTML][HTML] The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic

YR Woo, CJ Park, H Kang, JE Kim - International Journal of Molecular …, 2020 - mdpi.com
Psoriasis and psoriatic arthritis (PsA) have been recently considered as chronic systemic
inflammatory disorders. Over the past decades, enormous evidence indicates that patients …

Novel therapeutic approaches to psoriasis and risk of infectious disease

A Motolese, M Ceccarelli, L Macca, F Li Pomi… - Biomedicines, 2022 - mdpi.com
Psoriasis is a chronic immune-mediated skin and joint disease, with a plethora of
comorbidities, characterized by a certain genetic predisposition, and a complex …

Biologics Versus JAK Inhibitors. Part II: Risk of Infections. A Narrative Review

M Mansilla-Polo, D Morgado-Carrasco - Dermatology and Therapy, 2024 - Springer
Introduction The risk of infections associated with biological drugs (BD) and Janus kinase
inhibitors (JAKi) has been extensively explored in the literature. However, there is a dearth …

Treatment of psoriasis with biologic and non‐biologic targeted therapies in patients with latent tuberculosis infection or at risk for tuberculosis disease progression …

T Torres, NC Brembilla, RG Langley… - Journal of the …, 2025 - Wiley Online Library
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a significant global health
problem. In immunocompetent individuals, the microorganism can remain in a latent, non …

Risk of tuberculosis and hepatitis B reactivation in patients with Crohn's disease on ustekinumab: a nationwide real-world study

R Liu, Z Li, L Ye, J Hu, J Tang, B Chen… - Inflammatory Bowel …, 2024 - academic.oup.com
Background Ustekinumab (UST) was approved in China for moderate-to-severe Crohn's
disease (CD) in 2020. The prevalence rates of tuberculosis and hepatitis B virus (HBV) …

Infections in psoriatic arthritis: association with treatment

A Vassilopoulos, K Thomas… - Therapeutic Advances …, 2024 - journals.sagepub.com
Serious infections (SIs) remain one of the most significant comorbidities in patients with
inflammatory arthritides including psoriatic arthritis (PsA). Apart from methotrexate (MTX) …

A sco** review on the risk of tuberculosis in specific population groups: can we expand the World Health Organization recommendations?

J Bigio, A Viscardi, G Gore… - European Respiratory …, 2023 - publications.ersnet.org
Since 2015, the World Health Organization (WHO) has recommended prioritising testing and
treatment of tuberculosis (TB) infection (TBI) in 11 high-risk groups. With new options …

[HTML][HTML] [Translated article] Practical Update of the Guidelines Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (GPs) on …

JM Carrascosa, L Puig, IB Romero… - Actas dermo …, 2022 - Elsevier
Background and objectives Since its inception, the Psoriasis Group (GPs) of the Spanish
Academy of Dermatology and Venereology (AEDV) has worked to continuously update …

Disseminated Mycobacterial Infection With Reactive Polyarthritis (Poncet's Disease) During Immune-suppressive Treatment Including Ustekinumab for Pediatric …

C Minotti, P Costenaro, D Donà, M Zuliani… - The Pediatric …, 2024 - journals.lww.com
Background: The incidence of pediatric inflammatory bowel disease is increasing. tumor
necrosis factor alpha inhibitors medicines improved the prognosis of affected subjects …

Assessment and management for latent tuberculosis before advanced therapies for immune-mediated inflammatory diseases: A comprehensive review

DK Jha, R Kakadiya, A Sharma, S Naidu, D De… - Autoimmunity …, 2025 - Elsevier
Tuberculosis (TB), caused by Mycobacterium TB, is the most significant infectious cause of
mortality across the globe. While TB disease can prey on immunocompetent individuals, it is …